Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study

Modern Rheumatology

Volumn 28, Issue 1, 2018, Pages 20-29

  Tanaka, Yoshiya ^a   Ishii, Taeko ^b   Cai, Zhihong ^b   Schlichting, Douglas ^b   Rooney, Terence ^b   Macias, William ^b  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Arthritis, rheumatoid; baricitinib; inflammation; Janus kinase; Japan

Indexed keywords

BARICITINIB; C REACTIVE PROTEIN; METHOTREXATE; PLACEBO; ANTIRHEUMATIC AGENT; AZETIDINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; AMERICAN COLLEGE OF RHEUMATOLOGY; ARTICLE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HERPES ZOSTER; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE ASSESSMENT; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; COMBINATION DRUG THERAPY; MIDDLE AGED;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZETIDINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; SULFONAMIDES;

EID: 85018687009     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1080/14397595.2017.1307899     Document Type: Article

References (21)

1. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451–60.
2. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–86.
3. Tanaka Y., Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside. J Biochem. 2015;158:173–9.
4. Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184:5298–307.
5. Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol. 2016;43:504–11.
6. Kubo S, Nakayamada S, Tanaka Y., Baricitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2016;12:911–19.
7. Dougados M, van der Heijde D, Chen Y-C, Greenwald M, Drescher E, Liu J, et al. Baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in patients with active rheumatoid arthritis (RA) and an inadequate response to CDMARD therapy: results of the phase 3 RA-Build study. Ann Rheum Dis. 2015;74:79.
8. Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374:1243–52.
9. Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74:333–40.
10. Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69:506–17.
11. Keystone EC, Taylor PC, Genovese MC, Schlichting D, De La Torre I, Beattie SD, et al. Safety and efficacy of baricitinib through 128 weeks in an open-label, long-term extension study in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;64:S1049–S50.
12. Taylor P, Genovese M, Keystone E, Schlichting D, Beattie S, Macias W., Baricitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study. Ann Rheum Dis. 2014;73:A31.
13. Alamanos Y, Drosos AA., Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4:130–6.
14. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, III, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81.
15. Medical Dictionary for Regulatory Activities. Available from: http://www.meddra.org/.
16. US Department of Health and Human Services NIoH, National Cancer Institute. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. 2009.
17. Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016;18:34.
18. Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675–84.
19. Winthrop KL, Lindsey S, Weinblatt M, Takeuchi T, Hyslop D, Issa M, et al. Herpes Zoster in patients with moderate to severe rheumatoid arthritis treated with baricitinib. Arthritis Rheumatol. 2016;68(Suppl10).
20. Singh JA, Saag KG, Bridges SL, Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:1–25.
21. Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014;54:1354–61.